Abstract
Get full access to this article
View all access options for this article.
References
1.
Nahata M.C.
. New regulations for pediatric labeling of prescription drugs . Ann Pharmacother 1996 ; 30 : 1032 –33 .
2.
Shirkey H
. Editorial comment: therapeutic orphans . J Pediatr 1968 ; 72 : 119 –20 .
3.
Kearns G.L.
,
Reed M.D.
. Clinical pharmacokinetics in infants and children: a reappraisal . Clin Pharmacokinet 1989 ; 17 (suppl 1 ): 29 –67 .
4.
Kauffman R.E.
,
Kearns G.L.
. Pharmacokinetic studies in pediatric patients: clinical and ethical consideration . Clin Pharmacokinet 1992 ; 23 : 10 –29 .
5.
Wilson J.T.
,
Kearns G.L.
,
Murphy D
,
Yaffe S.J.
. Pediatric labeling requirements: implications for pharmacokinetic studies . Clin Pharmacokinet 1994 ; 26 : 308 –25 .
6.
Farrar H.C.
,
Wells T.G.
,
Kearns G.L.
. Paediatric clinical pharmacology: reclaiming the therapeutic orphan . Exp Opin Invest Drugs 1996 ; 5 : 7 –13 .
7.
Reed M.D.
,
Besunder J.B.
. Developmental pharmacology: ontogenic basis of drug disposition . Pediatr Clin North Am 1989 ; 36 : 1053 –74 .
8.
Kearns G.L.
. Pharmacogenetics and development: are infants and children at increased risk for adverse outcome? Curr Opin Pediatr 1995 ; 7 : 220 –33 .
9.
Rieder M.J.
. Mechanisms of unpredictable adverse drug reactions . Drug Safety 1994 ; 11 : 196 –212 .